news

AstraZeneca completes acquisition of Pearl Therapeutics

Posted: 28 June 2013 | | No comments yet

AstraZeneca announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics…

AstraZeneca

AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics, a privately held company based in Redwood City, California, focused on the development of inhaled small-molecule therapeutics for respiratory disease. Upon completion of the merger, AstraZeneca acquired 100% of Pearl’s shares.

As previously announced, the acquisition gives AstraZeneca access to a potential new treatment for chronic obstructive pulmonary disease (COPD), currently in late-stage development, and inhaler and formulation technology that provides a platform for future combination products

Related organisations

,